U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H24O7
Molecular Weight 388.4111
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VISNADINE

SMILES

CC[C@@H](C)C(=O)O[C@@H]1[C@H](OC(C)=O)C2=C(OC1(C)C)C=CC3=C2OC(=O)C=C3

InChI

InChIKey=GVBNSPFBYXGREE-CXWAGAITSA-N
InChI=1S/C21H24O7/c1-6-11(2)20(24)27-19-18(25-12(3)22)16-14(28-21(19,4)5)9-7-13-8-10-15(23)26-17(13)16/h7-11,18-19H,6H2,1-5H3/t11-,18-,19-/m1/s1

HIDE SMILES / InChI

Molecular Formula C21H24O7
Molecular Weight 388.4111
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Visnadine is a natural product extracted from the seeds and aerial parts of Ammi visnaga (Umbelliferae), plant widely used in Egyptian medicine since the Pharaohs times as antispastic and for the treatment of angina pectoris and other cardiovascular diseases. It has been used since a long time in western medicine for the treatment of various cardiac diseases and peripheral vasculopathies. Visnadine seems to act by inhibiting the contractile responses mediated by Ca2+ entry through L-type Ca2+ channels.Topical use of Visnadine may increase regional vascularization afecting turgidity and sensorial threshold of the area of application. A formulation for vulvar application (ReFeel® spray, IDI Integratori Dietetici Italiani S.r.l., Italy) has been developed and it contains Visnadine at high concentration (1%) with an elevate purity index (minimum 95%). Visnadine spray displayed positive effects on sexual function in women with and without FSD and it was well tolerated. Topical Visnadine may not only be part of multimodal strategies to manage clinically relevant sexual symptoms but also simply to help women to enhance their subjective impaired perception of sexual response.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
ReFeel
Primary
Unknown

PubMed

Sample Use Guides

In Vivo Use Guide
15 days, 1 application per day, with a vaginal cream containing visnadine, prenylflavonoids and bovine colostrum.
Route of Administration: Vaginal
In Vitro Use Guide
Visnadine (< 10(-5) M) selectively inhibited the contractions induced by depolarization with 80 mM KCl or by CaCl2 in rat KCl-depolarized aorta and the spontaneous activity of the portal vein. At concentrations higher than 10(-5) M, visnadine also inhibited the contractile responses induced by noradrenaline and phorbol 12-myristate 13-acetate (PMA), being equipotent to inhibit noradrenaline-induced contractions in either Ca(2+)-containing or Ca(2+)-free medium and PMA-induced contractions.
Substance Class Chemical
Record UNII
0RL4V0K263
Record Status Validated (UNII)
Record Version